6 research outputs found
Protocolo asistencial de deprescripción
Treball Final de Grau en Medicina. Codi: MD1158. Curs acadèmic: 2020/2021La deprescripción es el cese de un tratamiento de larga duración bajo la supervisión de
un profesional médico. En la actualidad, la esperanza de vida ha aumentado debido a la mejora
de las opciones terapéuticas, sin embargo esto ha provocado un aumento de las patologías
crónicas, y con ello el número de fármacos consumidos por paciente. La consecuencia de esto
es el aumento de interacciones farmacológicas o efectos adversos, disminuyendo la calidad de
vida.
El presente TFG ha consistido en la elaboración de un protocolo asistencial para los
profesionales de Atención Primaria del Departamento de Salud de Castellón. El protocolo tiene
el objetivo de establecer de forma estandarizada las pautas a seguir para realizar una correcta
deprescripción, y así mejorar la calidad asistencial en pacientes de 65 años o mayores. Para
ello, se ha realizado una búsqueda bibliográfica de la evidencia actual para aplicarla al
departamento de salud de Castellón. Se ha presentado una guía de deprescripción general, así
como de diferentes grupos farmacológicos relevantes en nuestro medio. También se han
elaborado algoritmos de deprescripción.Deprescription is the cessation of long-term treatment under the supervision of a
medical professional. Now the life expectancy has increased due to improve of therapeutic
options, however this leads to an increase of chronic diseases, and with it the number of drugs
consumed per patient. The consequence is the increment of drug-drug interactions or adverse
drugs events, decreasing quality of life.
The present DFP has involved the development of a practice protocol for primary
healthcare professionals of Castellon health department. The protocol aims to establish
guidelines for an accurate deprescription, and thus improve quality of care in patients aged 65
and over. To do so, a bibliographic search has been conducted on the current evidence and
then applied to Castellon health department. General deprescription guideline has been
introduced, as well as different relevant pharmacological groups in our setting. Deprescription
algorithms have been made too
NUTRARET: Effect of 2-Year Nutraceutical Supplementation on Redox Status and Visual Function of Patients With Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Trial
Oxidative stress plays a major role in the pathogenesis of retinitis pigmentosa (RP).
The main goal of this study was to evaluate the effect of 2-year nutritional intervention
with antioxidant nutraceuticals on the visual function of RP patients. Secondly, we
assessed how nutritional intervention affected ocular and systemic redox status. We
carried out a randomized, double-blind, placebo-controlled study. Thirty-one patients
with RP participated in the study. RP patients randomly received either a mixture
of nutraceuticals (NUT) containing folic acid, vitamin B6, vitamin A, zinc, copper,
selenium, lutein, and zeaxanthin or placebo daily for 2 years. At baseline and after 2-
year of the nutritional supplementation, visual function, dietetic-nutritional evaluations,
serum concentration of nutraceuticals, plasma and aqueous humor concentration of
several markers of redox status and inflammation were assessed. Retinal function
and structure were assessed by multifocal electroretinogram (mfERG), spectral
domain-optical coherence tomography (SD-OCT) and automated visual field (VF)
tests. Nutritional status was estimated with validated questionnaires. Total antioxidant
capacity, extracellular superoxide dismutase (SOD3), catalase (CAT), and glutathione
peroxidase (GPx) activities, protein carbonyl adducts (CAR) content, thiobarbituric acid
reactive substances (TBARS) formation (as indicator of lipid peroxidation), metabolites of the nitric oxide (NOX) and cytokine (interleukin 6 and tumor necrosis factor
alpha) concentrations were assessed by biochemical and immunological techniques
in aqueous humor or/and blood. Bayesian approach was performed to determine
the probability of an effect. Region of practical equivalence (ROPE) was used. At
baseline, Bayesian analysis revealed a high probability of an altered ocular redox status
and to a lesser extent systemic redox status in RP patients compared to controls.
Twenty-five patients (10 in the treated arm and 15 in the placebo arm) completed
the nutritional intervention. After 2 years of supplementation, patients who received
NUT presented better retinal responses (mfERG responses) compared to patients who
received placebo. Besides, patients who received NUT showed better ocular antioxidant
response (SOD3 activity) and lower oxidative damage (CAR) than those who received
placebo. This study suggested that long-term NUT supplementation could slow down
visual impairment and ameliorate ocular oxidative stress.This work was supported by the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO) Carlos III Health Institute (ISCIII) (Grant numbers: PI15/00052 and PI18/00252) and co-funded by the European Regional Development Fund (FEDER)/European Social Fund “A way to make Europe”/”Investing in your future.” It was also supported by the IIS La Fe-UV PROGRAMA VLC-BIOMED-I (NUTRARET) and by RETINA COMUNIDAD VALENCIANA. LO-G had an ISCIIIMedicin
RICORS2040 : The need for collaborative research in chronic kidney disease
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true
Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients.
BackgroundEfficient and early triage of hospitalized Covid-19 patients to detect those with higher risk of severe disease is essential for appropriate case management.MethodsWe trained, validated, and externally tested a machine-learning model to early identify patients who will die or require mechanical ventilation during hospitalization from clinical and laboratory features obtained at admission. A development cohort with 918 Covid-19 patients was used for training and internal validation, and 352 patients from another hospital were used for external testing. Performance of the model was evaluated by calculating the area under the receiver-operating-characteristic curve (AUC), sensitivity and specificity.ResultsA total of 363 of 918 (39.5%) and 128 of 352 (36.4%) Covid-19 patients from the development and external testing cohort, respectively, required mechanical ventilation or died during hospitalization. In the development cohort, the model obtained an AUC of 0.85 (95% confidence interval [CI], 0.82 to 0.87) for predicting severity of disease progression. Variables ranked according to their contribution to the model were the peripheral blood oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio, age, estimated glomerular filtration rate, procalcitonin, C-reactive protein, updated Charlson comorbidity index and lymphocytes. In the external testing cohort, the model performed an AUC of 0.83 (95% CI, 0.81 to 0.85). This model is deployed in an open source calculator, in which Covid-19 patients at admission are individually stratified as being at high or non-high risk for severe disease progression.ConclusionsThis machine-learning model, applied at hospital admission, predicts risk of severe disease progression in Covid-19 patients
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER); Agencia Española del Medicamento; Consejería de Salud de Andalucía.Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes